Health
CureVac starts clinical trial for COVID-19 vaccine candidate – Reuters India
German biotech firm CureVac has enrolled the first participant for a Phase 2b/3 clinical trial of its COVID-19 vaccine candidate, it said on Monday.
By Reuters Staff
FILE PHOTO: A vaccination against the coronavirus disease (COVID-19) from German biotechnology company CureVac is ready to use at the start of a clinical test series in the tropical institute of the university clinic in Tuebingen, Germany, June 22, 2020. REUTERS/Kai Pfaffenbach
BERLIN (Reuters) -German biotech firm CureVac has enrolled the first participant for a Phase 2b/3 clinical trial of its COVID-19 vaccine candidate, it said on Monday.
The trial, which is relevant for regulatory…
-
Noosa News14 hours agoWilliam Robinson dies aged 89
-
Business18 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Business18 hours agoWhat to do with these 3 ASX 200 retail shares after strong price runs: experts
-
General14 hours agoCalls for corruption probe into completion of mayor’s Surfers Paradise Bowls Club site purchase